Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

Rheumatology (United Kingdom)

Volumn 56, Issue 9, 2017, Pages 1498-1509

  van der Heijde, Désirée ^a   Dougados, Maxime ^b   Landewé, Robert ^c,d   Sieper, Joachim ^e   Maksymowych, Walter P ^f   Rudwaleit, Martin ^g   Van den Bosch, Filip ^h   Braun, Jürgen ⁱ   Mease, Philip J ^j   Kivitz, Alan J ^k   Walsh, Jessica ^l   Davies, Owen ^m   Bauer, Lars ^m   Hoepken, Bengt ^m   Peterson, Luke ^m   Deodhar, Atul ⁿ  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Institut Cochin   (France)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Zuyderland Medical Centre   (Netherlands)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF ALBERTA   (Canada)

^g Klinikum Bielefeld   (Germany)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ RHEUMAZENTRUM RUHRGEBIET   (Germany)

^j UNIVERSITY OF WASHINGTON   (United States)

^k Altoona Center for Clinical Research   (United States)

^l UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^m UCB PHARMA   (Belgium)

ⁿ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

Ankylosing spondylitis; Axial spondyloarthritis; Certolizumab pegol; Non radiographic axial spondyloarthritis

Indexed keywords

CERTOLIZUMAB PEGOL; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTHRITIS; ARTICLE; ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY 20; ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY 40; ASTROCYTOMA; BACKACHE; BASAL CELL CARCINOMA; BASMI SCORE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BREAST CANCER; CHOLELITHIASIS; CLINICAL OUTCOME; COLITIS; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; ENTHESITIS; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; LOADING DRUG DOSE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MOS SLEEP SCALE; MULTICENTER STUDY; MYCOBACTERIOSIS; NONCARDIAC CHEST PAIN; OPEN STUDY; OSTEOARTHRITIS; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; RENAL CELL CARCINOMA; SCORING SYSTEM; SHORT FORM 36; SIDE EFFECT; SPONDYLARTHRITIS; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; ULCERATIVE COLITIS; UTERINE CERVIX CANCER; UVEITIS; ADULT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS; CERTOLIZUMAB PEGOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 85019013385     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex174     Document Type: Article

References (32)

1. Linden SVD, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 1984;27:361-8
2. Rudwaleit M, van der Heijde D, Landewe R et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83
3. Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open 2015;1(Suppl 1):e000053
4. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and metaanalysis. Ann Rheum Dis 2015;74:65-73
5. Singh JA, Strand V. Spondyloarthritis is associated with poor function and physical health-related quality of life. J Rheumatol 2009;36:1012-20
6. Kiltz U, Baraliakos X, Karakostas P et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res 2012;64:1415-22
7. van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46
8. LandewéR, Braun J, Deodhar A et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:39
9. Davis JC Jr, Van Der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6
10. Sieper J, van der Heijde D, Dougados M et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebocontrolled trial (ABILITY-1). Ann Rheum Dis 2013;72:815-22
11. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93
12. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91
13. Inman RD, Davis JC Jr, Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12
14. Sieper J, van der Heijde D, Dougados M et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2015;67:2702-12
15. Maksymowych WP, Dougados M, van der Heijde D et al. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Ann Rheum Dis 2016;75:1328-35
16. Baraliakos X, Listing J, Brandt J et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-α antibody infliximab. Rheumatology 2007;46:1450-3
17. Braun J, Baraliakos X, Brandt J et al. Persistent clinical response to the anti-TNF-a antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 2005;44:670-6
18. Braun J, Baraliakos X, Hermann KG et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GORAISE trial. Ann Rheum Dis 2014;73:1107-13
19. van der Heijde DM, Revicki DA, Gooch KL et al. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Therapy 2009;11:R124
20. van der Heijde D, Breban M, Halter D et al. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5.years in a clinical trial of adalimumab. Rheumatology 2015;54:1210-9
21. van der Heijde D, Sieper J, Maksymowych WP, Baeten DL et al. Clinical response and remission in patients with nonradiographic axial spondyloarthritis after three years of adalimumab therapy. Arthritis Rheumatol 2014;66(Suppl 10):S247
22. Haibel H, Baraliakos X, Listing J, Braun J, Sieper J. Long term efficacy over five years of adalimumab in patients with active non-radiographic axial spondyloarthritis. Arthritis Rheumatol 2013;65(Suppl 10):S1055
23. Sieper J, LandewéR, Rudwaleit M et al. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. Arthritis Rheumatol 2015;67:668-77
24. LandewéR, van Tubergen A. Clinical tools to assess and monitor spondyloarthritis. Current Rheumatol Rep 2015;17:47
25. Sieper J, Kivitz A, van Tubergen A et al. Impact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritis. Arthritis Care Res 2015;67:1475-80
26. Zochling J, Braun J. Remission in ankylosing spondylitis. Clin Exp Rheumatol 2006;24:S88
27. Smolen JS, Braun J, Dougados M et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2013;73:6-16
28. Doward LC, Spoorenberg A, Cook SA et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20-6
29. van der Heijde D, Purcaru O, Kavanaugh A. FRI0439 High economic burden of axial spondyloarthritis related to paid work and household productivity at baseline in the rapidaxspa study: differences and similarities between ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 2013;72:A523-A4
30. Davis JC Jr, van der Heijde DM, Braun J et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52
31. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999;12:247-55
32. van Tubergen A, Black PM, Coteur G. Are patient-reported outcome instruments for ankylosing spondylitis fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysis. Rheumatology 2015;54:1842-51